Byterna Therapeutics
BR101 is a BCMA/CD19 circular mRNA in vivo CAR-T program in a registered IIT for relapsed/refractory myeloma (NCT07537049). Autoimmune development and BR102/BR103 are separately described as preclinical; their stages should not be inferred from BR101.
Corporate information
- Company entity
- Byterna Therapeutics
- Headquarters / principal office
- ShanghaiSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2023 ↗
- Ownership / capital status
- PrivatePre-A (July 2026; amount undisclosed) ↗
- Official corporate reference
- https://www.byterna.com/pipeline.html ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2026-07 · Pre-A · Undisclosed ↗
Company gives the month only; a day and amount are not inferred.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
BR101 is a BCMA/CD19 circular mRNA in vivo CAR-T program in a registered IIT for relapsed/refractory myeloma (NCT07537049). Autoimmune development and BR102/BR103 are separately described as preclinical; their stages should not be inferred from BR101.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Byterna Therapeutics — official page checked November 4, 2026
- Company-managed LinkedIn profile — self-reported location
- Corporate ownership / financing disclosure